JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $33
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $48 to $33.
Europe Approves Agios Pharma’s Mitapivat For Adult Pyruvate Kinase Deficiency Patients
The European Commission has approved Agios Pharmaceuticals Inc’s (NASDAQ:AGIO) Pyrukynd (mitapivat) for PK deficiency in adult patients. Pyrukynd is a first-in-class,…
Agios Pharmaceuticals: Q3 Earnings Insights
Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday’s Mid-Day Session
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split.
SVB Leerink Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $37
SVB Leerink analyst Andrew Berens maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price target from $33 to $37.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.